USANA Health Sciences (NYSE:USNA) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Wednesday, ValuEngine reports.

USNA has been the subject of several other reports. Tigress Financial started coverage on USANA Health Sciences in a report on Tuesday, April 16th. They set a “buy” rating for the company. Pivotal Research reiterated a “buy” rating and set a $105.00 price target on shares of USANA Health Sciences in a report on Wednesday, May 1st.

Shares of USANA Health Sciences stock opened at $75.78 on Wednesday. The stock has a market cap of $1.76 billion, a PE ratio of 14.69 and a beta of 0.30. USANA Health Sciences has a 52-week low of $75.09 and a 52-week high of $137.95.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.02. The business had revenue of $272.90 million during the quarter, compared to analyst estimates of $272.20 million. USANA Health Sciences had a return on equity of 29.51% and a net margin of 10.38%. The firm’s revenue was down 6.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 EPS. Sell-side analysts anticipate that USANA Health Sciences will post 5.18 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. NumerixS Investment Technologies Inc acquired a new stake in shares of USANA Health Sciences during the 4th quarter valued at about $34,000. Royce & Associates LP lifted its holdings in shares of USANA Health Sciences by 66.4% during the 1st quarter. Royce & Associates LP now owns 381 shares of the company’s stock valued at $32,000 after buying an additional 152 shares during the last quarter. Flagship Harbor Advisors LLC lifted its holdings in shares of USANA Health Sciences by 60.8% during the 4th quarter. Flagship Harbor Advisors LLC now owns 677 shares of the company’s stock valued at $79,000 after buying an additional 256 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of USANA Health Sciences by 23.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 858 shares of the company’s stock valued at $101,000 after acquiring an additional 165 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of USANA Health Sciences by 43.8% in the 4th quarter. Great West Life Assurance Co. Can now owns 1,516 shares of the company’s stock valued at $172,000 after acquiring an additional 462 shares in the last quarter. Institutional investors and hedge funds own 54.16% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Featured Story: What is a Buy-Side Analyst?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.